Thyroid Gland Disorder Treatment Market Overview:

Thyroid Gland Disorder Treatment Market is an endocrine gland that stimulates hormones, which help regulate the metabolism of the body. When the thyroid gland does not produce enough thyroid hormones (hypothyroidism) or too much hormone (hyperthyroidism), the metabolism and functioning of the body is disrupted. The lack of iodine in the body is a major factor that leads to thyroid disorder. It has been observed that more than 2 billion people are estimated to be at the risk of iodine deficiency worldwide, among which the developing countries have the highest number of undiagnosed patients. The global thyroid gland disorder market was valued at $2,057 million in 2017, and is estimated to reach $2,771 million by 2025 at a CAGR of 3.8% from 2018 to 2025.

The major factors that drive the growth of the market include increase in the incidence of thyroid gland disorder, rise in the number of disease awareness programs especially in the developing countries, and development of effective combination drug therapies to treat thyroid gland disorder. However, side effects of the drugs and stringent government regulations hamper the market growth. Moreover, availability of large pool of undiagnosed patients due to asymptomatic nature of thyroid disorders help open new avenues for the market growth during the forecast period.

Disease type segment review

Based on the disease type, the market is bifurcated into hypothyroidism and hyperthyroidism. The hypothyroidism segment dominates the market, owing to the high prevalence of iodine deficiency population worldwide, and is the most commonly occurring thyroid disorder.

Route of administration segment review

Based on route of administration, the market is classified into oral, intravenous, and others. Oral route of administration is the largest contributor toward the market growth as most of the medications available in the market are in the form of tablets or pills and can be easily administered by patients on daily basis.
 

Key geographical segment

As per region, the thyroid gland disorder treatment market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in 2017, and is expected to retain its dominance throughout the forecast period.
 

The key players operating in the global thyroid gland disorder treatment market include AbbVie Inc., Pfizer Inc., Merck & Co., Inc., Lannett Company, Inc., Allergan plc, Mylan N.V., GlaxoSmithKline plc, Novartis AG, RLC LABS, Inc., and Abbott Laboratories.

Other prominent players in the value chain include Takeda Pharmaceutical Company Limited, Aspen, Amgen Inc., Endo International plc, Acella Pharmaceuticals, LLC, and Gemini Laboratories, LLC.

Key Benefits

• This report entails a detailed quantitative analysis of the current market trends from 2017 to 2025 to identify the prevailing opportunities.
• Market estimations are based on comprehensive analysis of the key developments in the industry.
• The global market is comprehensively analyzed with respect to disease type, drug type, route of administration, distribution channels, and region.
• In-depth analysis based on region assists to understand the regional market to assist in strategic business planning.
• The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

 Key Market Segments

• By DISEASE TYPE
  • Hypothyroidism
  • Hyperthyroidism
• By DRUG TYPE
  • Levothyroxine
  • Liothyronine
  • Propylthiouracil
  • Imidazole-based compounds
  • Others
• By ROUTE OF ADMINISTRATION
  • Oral
  • Intravenous route
  • Others
• By DISTRIBUTION CHANNEL
  • Wholesaler/Distributor Retailer Mail-order Pharmacy Others
  • Retailer
  • Mail-Order Pharmacy
  • Others
• By GEOGRAPHY
  • North America
    • U.S
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

 
Key Market Players

• GlaxoSmithKline plc
• Abbott Laboratories
• Lannett Company, Inc
• Pfizer Inc
• Mylan N.V
• Novartis AG
• Merck & Co. Inc
• AbbVie Inc
• RLC LABS, Inc
• Allergan Plc

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

CHAPTER 2: EXECUTIVE SUMMARY

2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Market share analysis, 2017
3.4. Porters five forces analysis
3.5. Market dynamics

3.5.1. Drivers

3.5.1.1. Increase in incidence of thyroid gland disorders
3.5.1.2. Development of effective combination thyroid disorders drug therapies
3.5.1.3. Increase in number of disease awareness programs in developing regions

3.5.2. Restraints

3.5.2.1. Side effects that cause lesser patient adherence
3.5.2.2. Stringent government regulations

3.5.3. Opportunities

3.5.3.1. Availability of large pool of undiagnosed patients due to asymptomatic nature of thyroid disorders

CHAPTER 4: THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Hypothyroidism

4.2.1. Key market trends and growth opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country

4.3. Hyperthyroidism

4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country

CHAPTER 5: THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE

5.1. Overview

5.1.1. Market size and forecast

5.2. Levothyroxine

5.2.1. Market size and forecast
5.2.2. Market analysis, by country

5.3. Liothyronine

5.3.1. Market size and forecast
5.3.2. Market analysis, by country

5.4. Propylthiouracil

5.4.1. Market size and forecast
5.4.2. Market analysis, by country

5.5. Imidazole-based compounds

5.5.1. Market size and forecast
5.5.2. Market analysis, by country

5.6. Others

5.6.1. Market size and forecast
5.6.2. Market analysis, by country

CHAPTER 6: THYROID GLAND DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

6.1. Overview

6.1.1. Market size and forecast

6.2. Oral route

6.2.1. Market size and forecast
6.2.2. Market analysis, by country

6.3. Intravenous route

6.3.1. Market size and forecast
6.3.2. Market analysis, by country

6.4. Others

6.4.1. Market size and forecast
6.4.2. Market analysis, by country

CHAPTER 7: THYROID GLAND DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL

7.1. Overview

7.1.1. Market size and forecast

7.2. Wholesalers/Distributors

7.2.1. Market size and forecast
7.2.2. Market analysis, by country

7.3. Retailer

7.3.1. Market size and forecast
7.3.2. Market analysis, by country

7.4. Mail-Order Pharmacy

7.4.1. Market size and forecast
7.4.2. Market analysis, by country

7.5. Others

7.5.1. Market size and forecast
7.5.2. Market analysis, by country

CHAPTER 8: THYROID GLAND DISORDER TREATMENT MARKET, BY GEOGRAPHY

8.1. OVERVIEW

8.1.1. Market size and forecast

8.2. NORTH AMERICA

8.2.1. Key market trends and opportunities
8.2.2. North America thyroid gland disorder treatment market by disease type
8.2.3. North America thyroid gland disorder treatment market by drug type
8.2.4. North America thyroid gland disorder treatment market by route of administration
8.2.5. North America thyroid gland disorder treatment market by distribution channel
8.2.6. Market size and forecast, by country

8.2.6.1. U.S. thyroid gland disorder treatment market by disease type
8.2.6.2. U.S. thyroid gland disorder treatment market by drug type
8.2.6.3. U.S. thyroid gland disorder treatment market by route of administration
8.2.6.4. U.S. thyroid gland disorder treatment market by distribution channel
8.2.6.5. Canada thyroid gland disorder treatment market by disease type
8.2.6.6. Canada thyroid gland disorder treatment market by drug type
8.2.6.7. Canada thyroid gland disorder treatment market by route of administration
8.2.6.8. Canada thyroid gland disorder treatment market by distribution channel
8.2.6.9. Mexico thyroid gland disorder treatment market by disease type
8.2.6.10. Mexico thyroid gland disorder treatment market by drug type
8.2.6.11. Mexico thyroid gland disorder treatment market by route of administration
8.2.6.12. Mexico thyroid gland disorder treatment market by distribution channel

8.3. EUROPE

8.3.1. Key market trends and opportunities
8.3.2. Europe thyroid gland disorder treatment market by disease type
8.3.3. Europe thyroid gland disorder treatment market by drug type
8.3.4. Europe thyroid gland disorder treatment market by route of administration
8.3.5. Europe thyroid gland disorder treatment market by distribution channel
8.3.6. Market size and forecast, by country

8.3.6.1. Germany thyroid gland disorder treatment market by disease type
8.3.6.2. Germany thyroid gland disorder treatment market by drug type
8.3.6.3. Germany thyroid gland disorder treatment market by route of administration
8.3.6.4. Germany thyroid gland disorder treatment market by distribution channel
8.3.6.5. France thyroid gland disorder treatment market by disease type
8.3.6.6. France thyroid gland disorder treatment market by drug type
8.3.6.7. France thyroid gland disorder treatment market by route of administration
8.3.6.8. France thyroid gland disorder treatment market by distribution channel
8.3.6.9. UK thyroid gland disorder treatment market by disease type
8.3.6.10. UK thyroid gland disorder treatment market by drug type
8.3.6.11. UK thyroid gland disorder treatment market by route of administration
8.3.6.12. UK thyroid gland disorder treatment market by distribution channel
8.3.6.13. Italy thyroid gland disorder treatment market by disease type
8.3.6.14. Italy thyroid gland disorder treatment market by drug type
8.3.6.15. Italy thyroid gland disorder treatment market by route of administration
8.3.6.16. Italy thyroid gland disorder treatment market by distribution channel
8.3.6.17. Spain thyroid gland disorder treatment market by disease type
8.3.6.18. Spain thyroid gland disorder treatment market by drug type
8.3.6.19. Spain thyroid gland disorder treatment market by route of administration
8.3.6.20. Spain thyroid gland disorder treatment market by distribution channel
8.3.6.21. Rest of Europe thyroid gland disorder treatment market by disease type
8.3.6.22. Rest of Europe thyroid gland disorder treatment market by drug type
8.3.6.23. Rest of Europe thyroid gland disorder treatment market by route of administration
8.3.6.24. Rest of Europe thyroid gland disorder treatment market by distribution channel

8.4. Asia-Pacific

8.4.1. Key trends and opportunities
8.4.2. Asia-Pacific thyroid gland disorder treatment market by disease type
8.4.3. Asia-Pacific thyroid gland disorder treatment market by drug type
8.4.4. Asia-Pacific thyroid gland disorder treatment market by route of administration
8.4.5. Asia-Pacific thyroid gland disorder treatment market by distribution channel
8.4.6. Market size and forecast, by country

8.4.6.1. Japan thyroid gland disorder treatment market by disease type
8.4.6.2. Japan thyroid gland disorder treatment market by drug type
8.4.6.3. Japan thyroid gland disorder treatment market by route of administration
8.4.6.4. Japan thyroid gland disorder treatment market by distribution channel
8.4.6.5. China thyroid gland disorder treatment market by disease type
8.4.6.6. China thyroid gland disorder treatment market by drug type
8.4.6.7. China thyroid gland disorder treatment market by route of administration
8.4.6.8. China thyroid gland disorder treatment market by distribution channel
8.4.6.9. Australia thyroid gland disorder treatment market by disease type
8.4.6.10. Australia thyroid gland disorder treatment market by drug type
8.4.6.11. Australia thyroid gland disorder treatment market by route of administration
8.4.6.12. Australia thyroid gland disorder treatment market by distribution channel
8.4.6.13. India thyroid gland disorder treatment market by disease type
8.4.6.14. India thyroid gland disorder treatment market by drug type
8.4.6.15. India thyroid gland disorder treatment market by route of administration
8.4.6.16. India thyroid gland disorder treatment market by distribution channel
8.4.6.17. South Korea thyroid gland disorder treatment market by disease type
8.4.6.18. South Korea thyroid gland disorder treatment market by drug type
8.4.6.19. South Korea thyroid gland disorder treatment market by route of administration
8.4.6.20. South Korea thyroid gland disorder treatment market by distribution channel
8.4.6.21. Rest of Asia-Pacific thyroid gland disorder treatment market by disease type
8.4.6.22. Rest of Asia-Pacific thyroid gland disorder treatment market by drug type
8.4.6.23. Rest of Asia-Pacific thyroid gland disorder treatment market by route of administration
8.4.6.24. Rest of Asia-Pacific thyroid gland disorder treatment market by distribution channel

8.5. LAMEA

8.5.1. Key market trends and opportunities
8.5.2. LAMEA thyroid gland disorder treatment market by disease type
8.5.3. LAMEA thyroid gland disorder treatment market by drug type
8.5.4. LAMEA thyroid gland disorder treatment market by route of administration
8.5.5. LAMEA thyroid gland disorder treatment market by distribution channel
8.5.6. Market size and forecast, by country

8.5.6.1. Brazil thyroid gland disorder treatment market by disease type
8.5.6.2. Brazil thyroid gland disorder treatment market by drug type
8.5.6.3. Brazil thyroid gland disorder treatment market by route of administration
8.5.6.4. Brazil thyroid gland disorder treatment market by distribution channel
8.5.6.5. Saudi Arabia thyroid gland disorder treatment market by disease type
8.5.6.6. Saudi Arabia thyroid gland disorder treatment market by drug type
8.5.6.7. Saudi Arabia thyroid gland disorder treatment market by route of administration
8.5.6.8. Saudi Arabia thyroid gland disorder treatment market by distribution channel
8.5.6.9. South Africa thyroid gland disorder treatment market by disease type
8.5.6.10. South Africa thyroid gland disorder treatment market by drug type
8.5.6.11. South Africa thyroid gland disorder treatment market by route of administration
8.5.6.12. South Africa thyroid gland disorder treatment market by distribution channel
8.5.6.13. Rest of LAMEA thyroid gland disorder treatment market by disease type
8.5.6.14. Rest of LAMEA thyroid gland disorder treatment market by drug type
8.5.6.15. Rest of LAMEA thyroid gland disorder treatment market by route of administration
8.5.6.16. Rest of LAMEA thyroid gland disorder treatment market by distribution channel

CHAPTER 9: COMPANY PROFILES

9.1. Abbott Laboratories

9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product portfolio
9.1.5. Business performance

9.2. AbbVie Inc.

9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segment
9.2.4. Product portfolio
9.2.5. Business performance

9.3. Allergan Plc.

9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product portfolio
9.3.5. Business performance

9.4. GlaxoSmithKline plc

9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product portfolio
9.4.5. Business performance

9.5. Lannett Company, Inc.

9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance

9.6. Merck & Co. Inc.

9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product portfolio
9.6.5. Business performance

9.7. Mylan N.V.

9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Product portfolio
9.7.5. Business performance

9.8. Novartis AG

9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product portfolio
9.8.5. Business performance

9.9. Pfizer Inc.

9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product portfolio
9.9.5. Business performance

9.10. RLC LABS, Inc.

9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Product portfolio

LIST OF TABLES

TABLE 01. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2017-2025 ($MILLION)
TABLE 02. THYROID GLAND DISORDER TREATMENT MARKET FOR HYPOTHYROIDISM, BY REGION, 2017-2025 ($MILLION)
TABLE 03. THYROID GLAND DISORDER TREATMENT MARKET FOR HYPERTHYROIDISM, BY REGION, 2017-2025 ($MILLION)
TABLE 04. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
TABLE 05. THYROID GLAND DISORDER TREATMENT MARKET FOR LEVOTHYROXINE, BY REGION, 2017-2025 ($MILLION)
TABLE 06. THYROID GLAND DISORDER TREATMENT MARKET FOR LIOTHYRONINE, BY REGION, 2017-2025 ($MILLION)
TABLE 07. THYROID GLAND DISORDER TREATMENT MARKET FOR PROPYLTHIOURACIL, BY REGION, 2017-2025 ($MILLION)
TABLE 08. THYROID GLAND DISORDER TREATMENT MARKET FOR IMIDAZOLE-BASED COMPOUNDS, BY REGION, 2017-2025 ($MILLION)
TABLE 09. THYROID GLAND DISORDER TREATMENT MARKET FOR OTHER DRUG TYPES, BY REGION, 2017-2025 ($MILLION)
TABLE 10. GLOBAL THYROID GLAND DISORDER TREATMENT, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 11. GLOBAL THYROID GLAND DISORDER TREATMENT FOR ORAL ROUTE OF ADMINISTRATION, BY REGION, 2017-2025 ($MILLION)
TABLE 12. GLOBAL THYROID GLAND DISORDER TREATMENT FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2017-2025 ($MILLION)
TABLE 13. GLOBAL THYROID GLAND DISORDER TREATMENT FOR OTHER ROUTE OF ADMINISTRATION, BY REGION, 2017-2025 ($MILLION)
TABLE 14. GLOBAL THYROID GLAND DISORDER TREATMENT, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 15. GLOBAL THYROID GLAND DISORDER TREATMENT FOR WHOLESALERS/DISTRIBUTORS, BY REGION, 2017-2025 ($MILLION)
TABLE 16. GLOBAL THYROID GLAND DISORDER TREATMENT FOR RETAILER, BY REGION, 2017-2025 ($MILLION)
TABLE 17. GLOBAL THYROID GLAND DISORDER TREATMENT FOR MAIL-ORDER PHARMACY, BY REGION, 2017-2025 ($MILLION)
TABLE 18. GLOBAL THYROID GLAND DISORDER TREATMENT FOR OTHER DISTRIBUTION CHANNEL, BY REGION, 2017-2025 ($MILLION)
TABLE 19. GLOBAL THYROID GLAND DISORDER TREATMENT, BY REGION, 2017-2025 ($MILLION)
TABLE 20. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2017-2025 ($MILLION)
TABLE 21. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
TABLE 22. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 23. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 24. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 25. U.S. THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2017-2025 ($MILLION)
TABLE 26. U.S. THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
TABLE 27. U.S. THYROID GLAND DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 28. U.S. THYROID GLAND DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 29. CANADA THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2017-2025 ($MILLION)
TABLE 30. CANADA THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
TABLE 31. CANADA THYROID GLAND DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 32. CANADA THYROID GLAND DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 33. MEXICO THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2017-2025 ($MILLION)
TABLE 34. MEXICO THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
TABLE 35. MEXICO THYROID GLAND DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 36. MEXICO THYROID GLAND DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 37. EUROPE THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2017-2025 ($MILLION)
TABLE 38. EUROPE THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
TABLE 39. EUROPE THYROID GLAND DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 40. EUROPE THYROID GLAND DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 41. EUROPE THYROID GLAND DISORDER TREATMENT MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 42. GERMANY THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2017-2025 ($MILLION)
TABLE 43. GERMANY THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
TABLE 44. GERMANY THYROID GLAND DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 45. GERMANY THYROID GLAND DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 46. FRANCE THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2017-2025 ($MILLION)
TABLE 47. FRANCE THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
TABLE 48. FRANCE THYROID GLAND DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 49. FRANCE THYROID GLAND DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 50. UK THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2017-2025 ($MILLION)
TABLE 51. UK THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
TABLE 52. UK THYROID GLAND DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 53. UK THYROID GLAND DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 54. ITALY THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2017-2025 ($MILLION)
TABLE 55. ITALY THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
TABLE 56. ITALY THYROID GLAND DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 57. ITALY THYROID GLAND DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 58. SPAIN THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2017-2025 ($MILLION)
TABLE 59. SPAIN THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
TABLE 60. SPAIN THYROID GLAND DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 61. SPAIN THYROID GLAND DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 62. REST OF EUROPE THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2017-2025 ($MILLION)
TABLE 63. REST OF EUROPE THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
TABLE 64. REST OF EUROPE THYROID GLAND DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 65. REST OF EUROPE THYROID GLAND DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 66. ASIA-PACIFIC THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2017-2025 ($MILLION)
TABLE 67. ASIA-PACIFIC THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
TABLE 68. ASIA-PACIFIC THYROID GLAND DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 69. ASIA-PACIFIC THYROID GLAND DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 70. ASIA-PACIFIC THYROID GLAND DISORDER TREATMENT MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 71. JAPAN THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2017-2025 ($MILLION)
TABLE 72. JAPAN THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
TABLE 73. JAPAN THYROID GLAND DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 74. JAPAN THYROID GLAND DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 75. CHINA THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2017-2025 ($MILLION)
TABLE 76. CHINA THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
TABLE 77. CHINA THYROID GLAND DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 78. CHINA THYROID GLAND DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 79. AUSTRALIA THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2017-2025 ($MILLION)
TABLE 80. AUSTRALIA THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
TABLE 81. AUSTRALIA THYROID GLAND DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 82. AUSTRALIA THYROID GLAND DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 83. INDIA THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2017-2025 ($MILLION)
TABLE 84. INDIA THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
TABLE 85. INDIA THYROID GLAND DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 86. INDIA THYROID GLAND DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 87. SOUTH KOREA THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2017-2025 ($MILLION)
TABLE 88. SOUTH KOREA THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
TABLE 89. SOUTH KOREA THYROID GLAND DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 90. SOUTH KOREA THYROID GLAND DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 91. REST OF ASIA-PACIFIC THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2017-2025 ($MILLION)
TABLE 92. REST OF ASIA-PACIFIC THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
TABLE 93. REST OF ASIA-PACIFIC THYROID GLAND DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 94. REST OF ASIA-PACIFIC THYROID GLAND DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 95. LAMEA THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2017-2025 ($MILLION)
TABLE 96. LAMEA THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
TABLE 97. LAMEA THYROID GLAND DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 98. LAMEA THYROID GLAND DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 99. LAMEA THYROID GLAND DISORDER TREATMENT MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 100. BRAZIL THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2017-2025 ($MILLION)
TABLE 101. BRAZIL THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
TABLE 102. BRAZIL THYROID GLAND DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 103. BRAZIL THYROID GLAND DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 104. SAUDI ARABIA THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2017-2025 ($MILLION)
TABLE 105. SAUDI ARABIA THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
TABLE 106. SAUDI ARABIA THYROID GLAND DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 107. SAUDI ARABIA THYROID GLAND DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 108. SOUTH AFRICA THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2017-2025 ($MILLION)
TABLE 109. SOUTH AFRICA THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
TABLE 110. SOUTH AFRICA THYROID GLAND DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 111. SOUTH AFRICA THYROID GLAND DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 112. REST OF LAMEA THYROID GLAND DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2017-2025 ($MILLION)
TABLE 113. REST OF LAMEA THYROID GLAND DISORDER TREATMENT MARKET, BY DRUG TYPE, 2017-2025 ($MILLION)
TABLE 114. REST OF LAMEA THYROID GLAND DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 115. REST OF LAMEA THYROID GLAND DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 116. ABBOTT: COMPANY SNAPSHOT
TABLE 117. ABBOTT: OPERATING SEGMENTS
TABLE 118. ABBOTT: PRODUCT PORTFOLIO
TABLE 119. ABBVIE: COMPANY SNAPSHOT
TABLE 120. ABBVIE: OPERATING SEGMENT
TABLE 121. GSK: PRODUCT PORTFOLIO
TABLE 122. ALLERGAN: COMPANY SNAPSHOT
TABLE 123. ALLERGAN: OPERATING SEGMENTS
TABLE 124. ALLERGAN: PRODUCT PORTFOLIO
TABLE 125. GSK: COMPANY SNAPSHOT
TABLE 126. GSK: OPERATING SEGMENTS
TABLE 127. GSK: PRODUCT PORTFOLIO
TABLE 128. LANNETT: COMPANY SNAPSHOT
TABLE 129. LANNETT: OPERATING SEGMENTS
TABLE 130. GSK: PRODUCT PORTFOLIO
TABLE 131. MERCK: COMPANY SNAPSHOT
TABLE 132. MERCK: OPERATING SEGMENTS
TABLE 133. MERK: PRODUCT PORTFOLIO
TABLE 134. MYLAN: COMPANY SNAPSHOT
TABLE 135. MYLAN: OPERATING SEGMENTS
TABLE 136. MYLAN: PRODUCT PORTFOLIO
TABLE 137. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 138. NOVARTIS: OPERATING SEGMENTS
TABLE 139. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 140. PFIZER: COMPANY SNAPSHOT
TABLE 141. PFIZER: OPERATING SEGMENTS
TABLE 142. PFIZER: PRODUCT PORTFOLIO
TABLE 143. RLC LABS: COMPANY SNAPSHOT
TABLE 144. RLC LABS: OPERATING SEGMENTS
TABLE 145. RLC : PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. THYROID GLAND DISORDER TREATMENT MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS IN THE GLOBAL THYROID GLAND DISORDER TREATMENT MARKET
FIGURE 03. MARKET SHARE ANALYSIS, 2017
FIGURE 04. HIGH BARGAINING POWER OF BUYERS
FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
FIGURE 07. MODERATE THREAT OF SUBSTITUTION
FIGURE 08. MODERATE COMPETITIVE RIVALRY
FIGURE 09. COMPARATIVE SHARE ANALYSIS OF THYROID GLAND DISORDER TREATMENT MARKET FOR HYPOTHYROIDISM, BY COUNTRY, 2017 & 2025 (%)
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF THYROID GLAND DISORDER TREATMENT MARKET FOR HYPERTHYROIDISM, BY COUNTRY, 2017 & 2025 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF THYROID GLAND DISORDER TREATMENT MARKET FOR LEVOTHYROXINE, BY COUNTRY,2017 & 2025 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF THYROID GLAND DISORDER TREATMENT MARKET FOR LIOTHYRONINE, BY COUNTRY, 2017 & 2025 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF THYROID GLAND DISORDER TREATMENT MARKET FOR PROPYLTHIOURACIL, BY COUNTRY, 2017 & 2025 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF THYROID GLAND DISORDER TREATMENT MARKET FOR IMIDAZOLE-BASED COMPOUNDS, BY COUNTRY, 2017 & 2025 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF THYROID GLAND DISORDER TREATMENT MARKET FOR OTHER DRUG TYPES, BY COUNTRY, 2017 & 2025 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF THYROID GLAND DISORDER TREATMENT MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2017 & 2025 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF THYROID GLAND DISORDER TREATMENT MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2017 & 2025 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF THYROID GLAND DISORDER TREATMENT MARKET FOR OTHER ROUTE OF ADMINISTRATION, BY COUNTRY, 2017 & 2025 (%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF THYROID GLAND DISORDER TREATMENT MARKET FOR WHOLESALERS/DISTRIBUTORS, BY COUNTRY, 2017 & 2025 (%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF THYROID GLAND DISORDER TREATMENT MARKET FOR RETAILER, BY COUNTRY, 2017 & 2025 (%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF THYROID GLAND DISORDER TREATMENT MARKET FOR MAIL-ORDER PHARMACY, BY COUNTRY, 2017 & 2025 (%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF THYROID GLAND DISORDER TREATMENT MARKET FOR OTHER DISTRIBUTION CHANNEL, BY COUNTRY, 2017 & 2025 (%)
FIGURE 23. ABBOTT: NET SALES, 2015-2017 ($MILLION)
FIGURE 24. ABBOTT: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 25. ABBOTT: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 26. ABBVIE: NET SALES, 2015-2017 ($MILLION)
FIGURE 27. ABBVIE: NET SALES, BY GEOGRAPHY 2017 (%)
FIGURE 28. ALLERGAN: NET SALES, 2015-2017 ($MILLION)
FIGURE 29. ALLERGAN: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 30. GSK: NET SALES, 2015-2017 ($MILLION)
FIGURE 31. GSK: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 32. GSK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 33. LANNETT: NET SALES, 2015-2017 ($MILLION)
FIGURE 34. MERCK: NET SALES, 2015-2016 ($MILLION)
FIGURE 35. MERCK: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 36. MERCK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 37. MYLAN: NET SALES, 2015-2017 ($MILLION)
FIGURE 38. MYLAN: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 39. NOVARTIS: NET SALES, 2015-2017 ($MILLION)
FIGURE 40. NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 41. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 42. PFIZER: NET SALES, 2015-2017 ($MILLION)
FIGURE 43. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 44. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)